Eli Lilly and Company reported another record-breaking quarter for Q3 2025, with worldwide revenue surging 54% year-over-year to $17.60 billion, propelled by robust demand for its incretin-based therapies, Mounjaro and Zepbound. U.S. revenue increased by 45%, while international revenue soared 74%, driven by a 62% overall volume increase partially offset by lower realized prices. Adjusted earnings per share (EPS) reached $7.02, surpassing market expectations, and reported EPS climbed to $6.21.
Key growth drivers included Mounjaro, which generated $6.52 billion in sales—a 109% rise from last year—and Zepbound, which contributed $3.59 billion, marking a 185% annual increase. The company's R&D pipeline delivered significant advances, including positive Phase 3 results for orforglipron in type 2 diabetes and obesity, with regulatory submissions expected by yearend. Regulatory milestones featured FDA approval of Inluriyo (imlunestrant) for advanced breast cancer.
Buoyed by these results, Lilly raised its full-year 2025 guidance, projecting revenue in the range of $63.0 billion to $63.5 billion and adjusted EPS of $23.00 to $23.70. The company also announced new manufacturing facilities in Virginia and Texas, as well as an expansion in Puerto Rico, underscoring its long-term growth strategy.
CEO David A. Ricks noted that the quarter's results, pipeline progress, and expanded manufacturing signal continued momentum for Lilly’s innovation-driven expansion.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!